Business Wire

SHIN-ETSU-CHEMICAL

Share
Shin-Etsu Chemical Develops a New One-component Liquid Silicone Rubber Product That Is Superior in Vulcanization Characteristics and Safety

Shin-Etsu Chemical Co., Ltd., (Head Office: Tokyo; President: Yasuhiko Saitoh) has developed a new series of products, the KCP Series, a new vulcanization type of one-component liquid silicone rubber.

One-component liquid silicone rubber cures at room temperature by reacting to the atmospheric humidity. After curing, because it has superior combined characteristics, including heat resistance, cold resistance, weather resistance and outstanding electrical properties, it is used as adhesive/sealing materials and coating materials in such products as component parts for electric vehicles (EV), semiconductors, and electric/electronics. Furthermore, because it cures at room temperature, it is not necessary to have a heating furnace and ultraviolet (UV) irradiation equipment. Accordingly, these new products will contribute to reducing environmental impact.

The KCP Series of products are a type that releases cyclopentanone*1 at the time of the curing reaction. This new product series will meet the expectations of our customers with its improved vulcanization characteristics, higher level of safety and excellent handleability compared to existing products.*2 The main characteristics of these new products are as follows:

1: The vulcanization speed is fast and also the adhesion develops quickly, and thus work efficiency improves. The tack-free time*3 of KCP-102 is 3 minutes, ½ of the time of the existing KE-4898-W*4 product.

2: The odor that is generated at the time of curing is lower, and has a higher level of safety.

3: Because the ignition temperature is high, at more than 70 ℃, the handling time and effort needed during the time of transport and storage can be reduced.

4: It exhibits good adhesion with various resins and also there are almost no corrosive effects on metals.*5

There are 3 products lined up in the KCP Series according to their viscosity index: KCP-100 (low viscosity), KCP-101 (mid-viscosity) and KCP-102 (paste type). All of them are tube-type, and one can work simply by pushing the contents out from the tube-type container. Going forward, Shin-Etsu Chemical will continue to strive to meet the requests of our customers and develop products that have various added functions as we work to expand the line-up of our products.

Shin-Etsu Chemical will continue to endeavor to enhance our ability to contribute to the solution of various social and customer issues by developing and supplying advanced functional silicone products through making full use of the technological power and knowhow that Shin-Etsu has nurtured up to now, as we work to further contribute to the realization of the sustainability of society.

Footnotes:

*1 Cyclopentanone is an organic compound represented by the chemical formula (CH2 )4 CO. It is one of the cyclic ketones and is a volatile colorless liquid.

*2 Existing products include types of acetic acid, oxime, alcohol and acetone, and each have their own characteristics.

*3 It is the time that it takes until when one touches the surface, it will not stick to one’s finger.

*4 Curing Condition: 23℃/50%Relative Humidity

*5 Metal substrates should be tested prior to use with this product to insure performance.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Samsung Epis Holdings Delivers Business Updates at the 44th J.P. Morgan Healthcare Conference15.1.2026 01:40:00 CET | Press release

Samsung Bioepis plans to secure 20 biosimilars in its products and pipeline by 2030The new pipeline will include dupilumab, guselkumab, ixekizumab, fam-trastuzumab deruxtecan-nxki, vedolizumab, and ocrelizumab, in addition to pembrolizumab currently in Phase 1 and 3 clinical studiesHaving secured investigational new drug application (IND) clearance from the U.S. Food and Drug Administration (FDA), SBE303, Samsung Bioepis’ novel antibody-drug conjugate (ADC) engineered to target Nectin-4, will enter into the Phase 1 first-in-human clinical trial this yearSamsung Bioepis plans to add one novel therapeutic candidate in clinical study every year Samsung Epis Holdings (KRX: 0126Z0) today shared corporate progress and updates at the 44th J.P. Morgan Healthcare Conference. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260114206458/en/ Kyung-Ah Kim, President and Chief Executive Officer (CEO) of Samsung Epis Holdings "2026 is a mon

Most Delivered Light-Entry Jet Cessna Citation M2 Gen2 With Garmin Autothrottles Enters Into Service, Bringing Greater Control and Precision to Pilots14.1.2026 20:30:00 CET | Press release

The Cessna Citation M2 Gen2 with Garmin Autothrottles recently entered into service. Certified by the Federal Aviation Administration in October 2025, the integration of Garmin’s Autothrottle system in the Citation M2 Gen2 further supports the most delivered light-entry jet’s capabilities by bringing greater control and precision to pilots. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260114646844/en/ Most delivered light-entry jet Cessna Citation M2 Gen2 with Garmin Autothrottles enters into service, bringing greater control and precision to pilots (Photo Credit: Textron Aviation). The Cessna Citation M2 Gen2 is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company. “We continue to invest in our products to provide customers with the best aviation experience in the world," said Lannie O’Bannion, senior vice president, Sales & Marketing. “The M2 Gen2 leads its segment as the most delivered

TwentyTwo Real Estate and Farallon Capital Complete €761 Million Investment in Isemia, a €1.2bn Healthcare Real Estate Company Created With emeis14.1.2026 18:30:00 CET | Press release

TwentyTwo Real Estate, an independent European real estate investment and management firm, announces the completion, alongside Farallon Capital, of a €761 million investment that led to the creation of Isemia (www.isemiabyemeis.com), a leading healthcare real estate company holding a €1.2 billion portfolio of assets operated by emeis. The transaction represents a significant milestone in TwentyTwo Real Estate’s long-term investment strategy focused on healthcare and operational living real estate. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260114262830/en/ Fachklinik Schömberg Isemia comprises 68 high-quality assets across France, Germany and Spain, with a balanced mix of nursing homes (48%) and clinics (52%). The portfolio benefits from strong fundamentals and resilient operating performance. All properties will continue to be operated by emeis under long-term lease agreements, ensuring continuity of care for residents

AI’s Water Demand to Surge Nearly 130% by 2050 – New Research Shows How to Build a Water-Secure AI Economy14.1.2026 16:00:00 CET | Press release

Analysis finds AI could add 30 trillion liters of annual water demand, but targeted reuse and digital infrastructure investments can substantially offset demand and protect communities The rapid global expansion of artificial intelligence is set to drive a 129% increase in water demand across the AI value chain by 2050, according to new research by Xylem (NYSE: XYL) and Global Water Intelligence (GWI). Watering the New Economy: Managing the Impacts of the AI Revolution provides the most comprehensive assessment to date of how AI is reshaping global water use. It also highlights practical ways to meet that demand while strengthening water security for communities. Spending on AI is forecast to approach $2 trillion in 2026,1 accelerating infrastructure build-out worldwide. By the middle of the century, this expansion is projected to add 30 trillion liters of water demand, annually, fueled by a surge in power generation (~54% of the increase), semiconductor fabrication (~42%), and data ce

ACCELQ Crowned Leader and Customer Favorite in The Forrester Wave™ for Autonomous Testing Platforms14.1.2026 16:00:00 CET | Press release

Agentic Test Automation Pioneer Caps Record-Breaking Year of Growth and "AI-Based Engineering Solution of the Year" Honors Forrester has named ACCELQ a Leader in The Forrester Wave™: Autonomous Testing Platforms, Q4 2025. This marks the third consecutive Wave in which ACCELQ has been recognized as a Leader. Notably, this evaluation placed strong emphasis on generative AI innovation and real-world customer adoption. ACCELQ received the highest scores for both capabilities and vision and was the only platform to be recognized as a Customer Favorite, earning a "double halo" for exceptional customer endorsement. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260113112861/en/ ACCELQ recognized as a Leader and Customer Favorite in The Forrester Wave™️: Autonomous Testing Platforms, Q4 2025, validating its agentic, GenAI-embedded testing vision. According to the Forrester report, ACCELQ received the highest score among all evaluate

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye